Halogenated mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter

Journal of Medicinal Chemistry

Volumn 39, Issue 25, 1996, Pages 4935-4941

  Houlihan, William J ^a   Boja, John W ^b   Parrino, Vincent A ^c   Kopajtic, Theresa A ^b   Kuhar, Michael J ^b,d  

^a DREW UNIVERSITY   (United States)

^b NIDA Addiction Research Center   (United States)

^c Sandoz Pharma Ltd   (Switzerland)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 (3' CHLOROPHENYL) 2,3,4,6 TETRAHYDROPYRIMIDO[2,1 A]ISOINDOL 6 OL; 7 (3',4' DICHLOROPHENYL) 2,3,4,5 TETRAHYDRO 7H DIAZEPINO[2,1 A]ISOINDOL 7 OL; COCAINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; MAZINDOL; NEUROTRANSMITTER RECEPTOR; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HALOGENATION; MALE; NONHUMAN; RAT;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RATS;

EID: 0029731582     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960288w     Document Type: Article

References (79)

1. Stein, R. M.; Eillinwood, E. H. Medical Complications of Cocaine Abuse. Drug Therapy 1990, 40-50.
2. Cocaine: Scientific and Social Dimensions; Ciba Foundation Symposium Vol. 166; Bock, G. R., Whelan, J., Eds.; J. Wiley & Sons: New York, 1992; 306 pp.
3. Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology and Behavior; Redda, K. K., Walker, C. A., Barnett, G., Eds.; CRC Pres:, Boca Raton, FL, 1989; 238 pp.
4. National Institute on Drug Abuse Warning Network. National Clearinghouse for Drug and Alcohol Abuse Information, Rockville, MD, 1990.
5. Bates, C. K Medical Risks of Cocaine Use (Specialty Conference). West J. Med. 1988, 148, 440-444.
6. (a) Kabas, J. S.; Blanchard, S. M.; Matsuyama, Y.; et al. Cocaine-mediated Impairment of Cardiac Conduction in the Dog: A Potential Mechanism for Sudden Death After Cocaine. J. Pharmacol. Exp. Ther. 1990, 252, 185-199.
7. (b)Lange, R. A.; Cigarroa, R. G.; Flores, E. D. Potentiation of Cocaine-induced Coronary Vasoconstriction by Beta-adrenergic Blockage. Ann. Int. Med. 1990, 112, 897-903.
8. (c) Chokshi, S. K.; Moore, R.; Pandian, N. G.; Isner, J. M. Reversible Cardiomyopathy Associated with Cocaine Intoxication. Ann. Intern. Med. 1989, 111, 1039-1040.
9. (d) Cregler, L. L.; Mark H. Medical Complications of Cocaine Abuse. N. Engl. J. Med. 1986, 315, 1495-1499.
10. Rowbotham, M. C. Neurologic Aspects of Cocaine Use. West J. Med. 1988, 149, 442-448.
11. (a) American Psychiatric Association: Diagnostic and Statistical Manual, 3rd ed.; American Psychiatric Press: Washington, DC, 1987.
12. (b) Merriam, A. E.; Medalla, A.; Levine, B. Partial Complex Status Epilepticus Associated with Cocaine Abuse. Biol. Psychiatry 1988, 23, 515-518.
13. Volpe, J. J. Effect of Cocaine Use on the Fetus. N. Engl. J. Med. 1992, 327, 399-407.
14. Fullilove, R. E.; Fullilove, M. T.; Bowser, B. P.; Gross, S. A. Risk of Sexually Transmitted Disease Among Adolescent Crack Users in Oakland and San Francisco, Calif. J. Am. Med. Assoc. 1990, 263, 250-256.
15. Edlin, B. R.; Irwin, K. L.; Faruque, S.; McCoy, C. B.; Word, C.; Serrano, Y.; Inciard J. A.; Bowser, B. P.; Schilling, R. F.; Holmburg, S. D. Intersecting Epidemics-Crack Cocaine Use and HIV Infection Among Inter-City Young Adults. N. Engl. J. Med. 1992, 331, 1422-1427.
16. MacDonald, K. L.; Rutherford, G. W.; Friedman, S. M.; et al. Botulism and Botulism-like Illness in Chronic Drug Abusers. Ann. Intern. Med. 1985, 102, 616-618.
17. Wetli, C. V.; Weiss, S. D.; Cleary, T. J.; Gyori, B. Fungal Cerebritis from Intravenous Drug Abuse. J. Forensic Sci. 1984, 29 260-268
18. (a) Blackburn, K. J.; French, P. C.; Merrills, R. J. 5-Hydroxytryptamine Uptake by Rat Brain in vitro. Life Sci. 1967, 6, 260-268.
19. (b) Coyle, J. T.; Snyder, S. H. Antiparkinsonian Drugs; Inhibition of Dopamine Uptake in the Corpus Striatum as a Possible Mechanism of Action. Science 1969, 166, 889-901.
20. Ross, S. B.; Renyi, A. L. Inhibition of the Uptake of Tritiated 5-Hydroxytryptamine in Brain Tissues. Eur. J. Pharmacol. 1969, 7, 270-277.
21. 3H] Catecholamines by Homogenates of Rat Corpus Striatum and Cerebral Cortex: Effects of Amphetamine Analogue. Neuropharmacology 1973, 12, 669-679.
22. (e) Horn, A. S.; Cuello, C.; Miller, R. J. Dopamine in the Mesolimbic System of the Rat Brain: Endogenous Levels and the Effect of Drugs on the Uptake Mechanism and Stimulation of Adenylate Cyclase Activity. J. Neurochem. 1974, 22, 265-270.
23. 3H] Mazindol Binding Associates with Neural Dopamine and Norepinephrine Uptake Sites. Mol. Pharmacol. 1984, 26, 35-44.
24. Sharkey, J.; Glen, K. A.; Wolfe, F.; Kuhar, M. J. Cocaine Binding at Sigma Receptors. Eur. J. Pharmacol. 1988, 246, 1048-1052.
25. Sharkey, J.; Ritz, M. C.; Sehenden, J. A.; Hanson, R. C.; Kuhar, M. J. Cocaine Inhibits Muscarinic Cholinergic Receptor in Heart and Brain. J. Pharmacol. Exp. Ther. 1988, 246, 1048-1052.
26. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine Receptors on Dopamine Transporters are Related to Self-Administration of Cocaine. Science 1967, 237, 1219-1223.
27. (a) Kuhar, M. J.; Ritz, M. C.; Sharkey, J. Cocaine Receptors on Dopamine Transporters Mediate Cocaine-reinforced Behavior in Mechanisms of Cocaine Abuse and Toxicity; Clouet, D., Asghar, K. and Brown, R., Eds.; US Government Printing Office, Washington, DC, 1988; pp 14-22.
28. (b) Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The Dopamine Hypothesis of the Reinforcing Properties of Cocaine. Trends Neurosci. 1991, 14, 299-302.
29. Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine receptor: Biochemical Characterization and Structure-activity Relationships of Cocaine Analogues at the Dopamine Transporter. J. Med. Chem. 1992, 35, 969-981.
30. (a) Rothman, R. B. High Affinity Dopamine Reuptake Inhibitors as Potential Cocaine Antagonists: A Strategy for Drug Development. Life Sci. 1990, 46, 17-21.
31. (b) For other treatment approaches, see: Carroll, F. I.; Lewis, A. H.; Biswas, J. Chemical Approaches to the Treatment of Cocaine Abuse. Pharmaceut. News 1994, 1, 11-17.
32. (a) Silveretone, T. Appetite Suppressants. A Review. Drugs 1992, 43, 820-836.
33. (b) Coakley, J. H.; Moorcraft, J.; Hipkin, L. J.; Smith, C. S.; Griffiths, R. D.; Edwards, R. H. The Effect of Mazindol on Growth Hormone Secretion in Boys with Duchenne Muscular Dystrophy. J. Neurol. Neurosurg. Psychiatry 1988, 51, 1551-1557.
34. (c) Zatz, M.; Rapaport, D.; Pavanello, R. C.; Rocha, J. M.; Vainzof, M.; Nicolau, W. Nocturnal Rhythm of Growth Hormone in Duchenne Patients: Effects of Different Doses of Mazindol and Cyproheptadine. Am. J. Med. Genet. 1989, 33, 457-467.
35. (d) Griggs, R. C.; Moxley, R. T.; Mendell, J. R.; Fenichel, G. M.; Brooke, M. H.; Miller, P. J.; Mandel, S.; Florence, J.; Schierbecker, J.; Kaiser, K. K. Randomized Double-Blind Trial of Mazindol in Duchenne Dystrophy. Muscle Nerve 1990, 13, 1169-1173.
36. (a) Aeberli, P.; Eden, P.; Gogerty, J. H.; Houlihan, W. J.; Penberthy, C. 5-Aryl-2,3-dihydro-5H-imidazo [2,1-a] isoindol-5-ols. A Novel Class of Anorectic Agents, J. Med. Chem. 1975, 18, 177-182.
37. (b) Gogerty, J. H.; Penberthy, C.; Iorio, L. C.; Trapold, J. H. Pharmacological Analysis of a New Anorexic Substance: 5-Hydroxy-5-(4′chlorophenyl)-2,3 dihydro-5H-imidazo (2,1-a) isoindole (Mazindol). Arch. Int. Pharmacodyn. 1975, 214, 285-307.
38. (c) Angel, I.; Taranger, M. A.; Claustre, Y.; Scatton, B.; Langer, S. A. Anorectic Activities of Serotonin Uptake Inhibitors: Correlation with Their Potencies at Inhibiting Serotonin Uptake In Vivo and 3H-Mazindol Binding In Vitro. Life Sci. 1988, 43, 651-658.
39. (a) Heikkila, R. E.; Cabbat, F. S.; Manzino, L.; Babington, R. G.; Houlihan, W. J. Unexpected Differences between Mazindol and its Homologs on Biochemical and Behavioral Responses. J. Pharmacol. Exp. Ther. 1981, 277, 745-749.
40. (b) Heikkila, R. E.; Babington, R. G.; Houlihan, W. J. Pharmacological Studies with Several Analogs of Mazindol: Correlation Between Effects on Dopamine Uptake and Various in vivo Responses. Eur. J. Pharmacol. 1981, 71, 277-286.
41. (c) Engstrom, R. G.; Kelly, L. A. and Gogerty, J. H. The Effects of 5-Hydroxy-5-(4′-chlorophenyl)-2,3-dihydro-5-H-imidazo(2,1-a) isoindole (Mazindol, SaH 42-548) on the Metabolism of Brain Norepinephrine. Arch. Int. Pharmacodyn. Ther. 1975, 214, 308-321.
42. (a) Giros, B.; Caron, M. G. Molecular Characterization of the Dopamine Transporter. Trends Pharmacol. Sci. 1993, 14, 43-44.
43. (b) Kozikowski, A. P.; Liang, L.; Tanaka, J.; Bergmann, J. S.; Johnson, K. M. Use of Nitrile Oxide Cycle Addition (NOC) Chemistry in the Synthesis of Cocaine Analogues; Mazindol Binding and Dopamine Uptake Studies. Med. Chem. Res. 1991, 1, 312-321.
44. 3H] Mazindol Binding Sites from Alkylation by N-Ethylmaleamide. Eur. J. Pharmacol. 1992, 227, 411-415.
45. (b) Reith, M. E.; Selmeci, G. Radiolabeling of Dopamine Uptake Sites in Mouse Striatum; Comparison of Binding Sites for Cocaine, Mazindol and GBR 12935. Naunyn Schmiedesbergs Arch. Pharmacol. 1992, 345, 309-318.
46. Izenwasser, S.; Terry, P.; Heller, B.; Witkin, J. M.; Katz, J. L. Differential Relationships among Dopamine Transporter Affinities and Stimulant Potencies of Various Uptake Inhibitors. Eur. J. Pharmacol. 1994, 263, 277-283.
47. Bennett, B. A.; Hyde, C. E.; Pecora, J. R.; Clodfelter, J. E. Differing Neurotoxic Potencies of Methamphetamine, Mazindol and Cocaine in Mesencephalic Cultures. J. Neurochem. 1993, 60, 1444-1452.
48. Eshleman, A. J.; Henningsen, R. A.; Neve, K. A.; Janowsky, A. Release of Dopamine via the Human Transporter. Mol. Pharmacol. 1994, 45, 312-316.
49. (a) Chait, L. D.; Uhlenhuth, E. H.; Johanson, C. E. Reinforcing and Subjective Effects of Several Anorectics in Normal Human Volunteers. J. Pharmacol. Exp. Ther. 1987, 242, 777-783.
50. (b) Chait, L. D.; Uhlenhuth, E. H.; Johanson, C. E. The Discriminative Stimulus and Subjective Effects of Phenylpropanolamine, Mazindol and d-Amphetamine in Humans. Pharmacol. Biochem. Behavior 1986, 24, 1665-1672.
51. (c) DeFelice, E. A.; Bronstein, S.; Cohen, A. Double-blind Comparison of Placebo and 42-548, a New Appetite Suppressant, in Obese Volunteers. Curr. Res. Ther. 1969, 11, 256-262.
52. (d) Gotetam, K. G.; Gunne, L. M. Subjective Effects of Two Anorexigenic Agents Fenfluramine and AN-448 in Amphetamine-dependent Subjects. Br. J. Addict. 1972, 67, 39-44.
53. (e) Gotestam, K. G. Investigations of abuse potential of anorectic drugs. Curr. Med. Res. Opin. 1979, 6, 125-134.
54. (f) Chambers, C. D. The Epidemiology of Stimulant Abuse: A Focus on the Amphetamine-related Substances. In Amphetamine Use, Misuse and Abuse: Proceedings of the National Amphetamine Conference, 1978; Smith, D. E., Wesson, D. R., Buxton, M. E., Seymour, R. B., Ungerledider, J. T., Morgan, J. P. Mandell, A. J., Jara, G., Eds.; G. K. Hall and Co.: Boston, MA, 1979; pp 92-103.
55. (a) Wilson, M. C.; Schuster, C. R. Mazindol Self-Administration in the Rhesus Monkey. Pharmacol. Biochem. Behav. 1976, 4, 207-210.
56. (b) Corwin, R. L.; Woolverton, W. L.; Schuster, C. R.; Johanson, C. E. Anorectics: Effects on Food Intake and Self-administration in Rhesus Monkeys. Alcohol Drug Res. 1987, 7, 351-361.
57. (c) Yanagita, T.; Wakasa, Y.; Oinuma, N. Drug Dependence Potential of Mazindol Tested in Rhesus Monkeys. Jitchuken Zenrinsho Kenkyuho 1982, 8, 247-257.
58. (d) Risner, M. E.; Silcox, D. L. Psychostimulant Self-Administration by Beagle Dogs in a Progressive-ratio Paradigm. Psychopharmacology 1981, 75, 25-30.
59. (e) Spealman, R. D.; Madras, B. K.; Bergman, J. Effects of Cocaine and Related Drugs in Nonhuman Primates. II. Stimulant Effects on Schedule-Controlled Behavior. J. Pharmacol. Exp. Ther. 1989, 257, 142-149.
60. (f) Kleven, M. S.; Woolverton, W. L. Effects of Three Monoamine Uptake Inhibitors on Behavior Maintained by Cocaine or Food Presentation in Rhesus Monkeys. Drug Alcohol Depend. 1993, 37, 149-158.
61. (g) Mansbach, R. S.; Balster, R. L. Effects of Mazindol on Behavior Maintained or Occasioned by Cocaine. Drug Alcohol Depend. 1993, 31, 183-191.
62. Bergman, J.; Madras, B. K.; Johnson, S. E.; Spealman, R. D. Effects of Cocaine and Related Drugs in Nonhuman Primates. III. Self-Administration by Squirrel Monkeys. J. Pharmacol. Exp. Ther. 1989, 251, 150-155.
63. (a) Berger, P.; Gawin, F.; Koster, T. R. Treatment of Cocaine Abuse with Mazindol. Lancet 1989, No. 2, 283.
64. (b) Diakogiannis, I. A.; Steinberg, M.; Kosten, T. R. Mazindol Treatment of Cocaine Abuse. A Double-blind Investigation. In Problems of Drug Dependence 1990;: Proceeding of the 52nd Annual Scientific Meeting of The Committee on Problems of Drug Dependence, Inc.; Harris, L., Ed.; National Institute on Drug Abuse: Rockville, MD, 1990; p 514.
65. (c) Preston, K. L.; Sullivan, J. T.; Berger, P.; Bigelow, G. E. Effects of Cocaine Alone and in Combination with Mazindol in Human Cocaine Abusers. J. Pharmacol. Exp. Ther. 1993, 267, 296-307.
66. Margolin, A.; Avants, S. K.; Kosten, T. R. Mazindol for Relapse Prevention to Cocaine Abuse in Methadone - Maintained Patients. Am. J. Drug Alcohol Abuse 1995, 21, 469-481.
67. Houlihan, W. J.; Parrino, V. A. Directed Lithiation of 2-Phenyl-and 2-(o-Methylphenyl) imidazoline. J. Org. Chem. 1982, 47, 5177-5180.
68. Galinier, E.; Garreau, L.; Dognon, A. M.; Ombetta-Goka, J. E.; Frangin, Y.; Chalon, S.; Besnard, J. C., Guilloteau, D. Synthesis of Halogenated Analogs of 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo [2,1-a] isoindole or Mazindol for Exploration of the Dopamine Transporter. Eur. J. Med. Chem. 1993, 28, 927-933.
69. Aeberli, P.; Eden, P.; Gogerty, J. H.; Houlihan, W. J.; Penberthy, C. Anorectic Agents. 2. Structural Analogs of 5-(p-Chlorophenyl)-2,3-dihydro-5H-imidazo [2,1-a] isoindol-5-ol. J. Med. Chem. 1975, 18, 182-185.
70. Deutsch, H. M.; Shi, Q.; Gruszecka-Kowalik, E.; Schweri, M. Synthesis and Pharmacology of Potential Cocaine Antagonists. 2. Structure-Activity Relationship Studies of Aromatic Ring-Substituted Methylphenidate Analogs. J. Med. Chem. 1996, 39, 1201-1209.
71. Davies, H. M. L.; Saikali, E.; Huby, N. J. S.; Gilliatt, V. J.; Matasi, J. J.; Sexton, T.; Childers, S. R. Synthesis of 2β-Acyl-3β-aryl-8-azabicyclo [3.2.1] octanes and Their Binding Affinities at Dopamine and Serotonin Transporter Sites in Rat Striatum and Frontal Cortex. J. Med. Chem. 1994, 37, 1262-1268.
72. Yu, D.-W.; Gatley, S. J.; Wolf, A. P.; MacGregor, R. R.; Dewey, S. L.; Fowler, J. S.; Schyler, D. J. Synthesis of Carbon-11 Labeled Iodinated Cocaine Derivatives and Their Distribution in Baboon Brain Measured Using Positron Emission Tomography. J. Med. Chem. 1992, 35, 2178-2183.
73. Carroll, F. L; Gao, Y.; Rahman, M. A.; Abraham, P.; Parham, K.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Synthesis, Ligand Binding, QSAR and CoMFA Study of 3β-(p-Substituted phenyl) tropane-2β-carboxylic Acid Methyl Esters. J. Med. Chem. 1991, 34, 2719-2725.
74. W. J. Houlihan, unpublished results.
75. Kozikowski, A. P.; Eddine Saiah, M. K.; Bergmann, J. S.; Johnson, K. M. Structure-Activity Relationship Studies of N-Sulfonyl Analogs of Cocaine: Role of Ionic Interaction in Cocaine Binding. J. Med. Chem. 1994, 37, 3440-3442.
76. Koe, B. K. Molecular Geometry of Inhibitors of the Uptake of Catecholamines and Serotonin in Synaptosomal Preparations of Rat Brain. J. Pharmacol. Exp. Ther. 1976,199, 649-661.
77. Hoffman, B. J. Molecular Biology of Dopamine Transporters. In Dopamine Receptors and Transporters; Niznik, H. B., Ed.; Marcel Dekker, Inc.: New York, 1994; pp 645-668.
78. Oxley, P.; Short, W. F. Amidines. Part VI. Preparation of 2-substituted 4:5-dihydroglyoxalin and Ring Homologues from Cyanides and Alkylenediamines. J. Chem. Soc. 1947, 97-505.
79. 1H δ 0.87 (s, 3H), 0.91 (s, 3H), 2.90 (d, 1H), 2.99 (d, 1H), 3.12 (s, 2H), 6.81 (s, 1H), 7.20 (m, 1H), 7.32-7.51 (m, 6H), 7.70 (m, 1H).